Released Mar 28, 2013, after the close
10-K filed Mar 29, 2013, 88 days after period end · 0001019687-13-001065
Q4 2012 · 10-K
Revenue$5.93M$5.93M −2.8% vs Q4 2011−1.9% vs Q3 2012
Net Income$629.00K$629.00K N/M vs Q4 2011+1,064.8% vs Q3 2012
EPS Diluted$0.01$0.01 N/M vs Q4 2011no prior Q3 2012 on file
Operating Income$479,000N/M
Operating Cash Flowderived$1,162,000N/M
Free Cash Flowderived$902,000N/M
Margins · derived
Operating margin8.1%+22.9 pt vs Q4 2011
Net margin10.6%+27.6 pt vs Q4 2011
What the release said
The release
Same quarter
| Metric | Q4 2012 | Q4 2011 | Q4 2010dderived from reported figures |
|---|---|---|---|
| Revenue | $5.93M | $6.10M | — |
| Net Income | $629.00K | -$1.04M | — |
| EPS Diluted | $0.01 | -$0.02 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR